Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above

Research output: Contribution to journalJournal articlepeer-review

Standard

Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above. / Rebolj, Matejka; Bonde, Jesper; Preisler, Sarah; Ejegod, Ditte; Rygaard, Carsten; Lynge, Elsebeth.

In: P L o S One, Vol. 11, No. 1, e0147326, 20.01.2016, p. 1-14.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Rebolj, M, Bonde, J, Preisler, S, Ejegod, D, Rygaard, C & Lynge, E 2016, 'Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above', P L o S One, vol. 11, no. 1, e0147326, pp. 1-14. https://doi.org/10.1371/journal.pone.0147326

APA

Rebolj, M., Bonde, J., Preisler, S., Ejegod, D., Rygaard, C., & Lynge, E. (2016). Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above. P L o S One, 11(1), 1-14. [e0147326]. https://doi.org/10.1371/journal.pone.0147326

Vancouver

Rebolj M, Bonde J, Preisler S, Ejegod D, Rygaard C, Lynge E. Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above. P L o S One. 2016 Jan 20;11(1):1-14. e0147326. https://doi.org/10.1371/journal.pone.0147326

Author

Rebolj, Matejka ; Bonde, Jesper ; Preisler, Sarah ; Ejegod, Ditte ; Rygaard, Carsten ; Lynge, Elsebeth. / Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above. In: P L o S One. 2016 ; Vol. 11, No. 1. pp. 1-14.

Bibtex

@article{ee2391b0b40049adb61775ee46100a0b,
title = "Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above",
abstract = "In women aged ≥30 years, Human Papillomavirus testing will replace cytology for primary cervical screening. We compared Hybrid Capture 2 (HC2), cobas, CLART, and APTIMA HPV assays with cytology on 2869 SurePath samples from women undergoing routine screening at 30-65 years in Copenhagen, Denmark. Women with cytological abnormalities were managed according to routine recommendations, with 92% completeness. Those with cytology-normal/HPV-positive samples (on any of the four assays) were invited for repeated cytology and HPV testing in 1.5 year, and 58% had additional testing. HPV testing detected more ≥CIN3 than cytology (HC2: 35, cobas, CLART: 37, APTIMA: 34, cytology: 31), although statistically the differences were not significant. Cobas and CLART detected significantly more ≥CIN2 than cytology (cobas, CLART: 49, cytology: 39). The proportion of women with false-positive test results (positive test results without ≥CIN3) varied between 3.3% with cytology and 14.9% with cobas. All HPV assays led to significantly more false-positive tests, whereas compared to HC2 cobas and CLART were associated with a significantly higher and APTIMA with a significantly lower proportion. Detection of CIN1 was particularly increased for the three DNA assays. With APTIMA combined with cytological triage, about 20% more women were referred for colposcopy than with cytology screening. With the three DNA assays, the increase was ≥50%. The number of women with repeated testing was twice as high with APTIMA and almost five times as high with cobas compared to cytology. To our knowledge, Horizon was the only study set in routine practice that compared more than two HPV assays in the same women while also ascertaining the histological status of women with normal cytology/HPV-positive test results. HPV-based screening of Danish women aged 30-65 detected more high-grade CIN but decreased the screening specificity, and increased the demand for additional testing.",
author = "Matejka Rebolj and Jesper Bonde and Sarah Preisler and Ditte Ejegod and Carsten Rygaard and Elsebeth Lynge",
year = "2016",
month = jan,
day = "20",
doi = "10.1371/journal.pone.0147326",
language = "English",
volume = "11",
pages = "1--14",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

RIS

TY - JOUR

T1 - Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above

AU - Rebolj, Matejka

AU - Bonde, Jesper

AU - Preisler, Sarah

AU - Ejegod, Ditte

AU - Rygaard, Carsten

AU - Lynge, Elsebeth

PY - 2016/1/20

Y1 - 2016/1/20

N2 - In women aged ≥30 years, Human Papillomavirus testing will replace cytology for primary cervical screening. We compared Hybrid Capture 2 (HC2), cobas, CLART, and APTIMA HPV assays with cytology on 2869 SurePath samples from women undergoing routine screening at 30-65 years in Copenhagen, Denmark. Women with cytological abnormalities were managed according to routine recommendations, with 92% completeness. Those with cytology-normal/HPV-positive samples (on any of the four assays) were invited for repeated cytology and HPV testing in 1.5 year, and 58% had additional testing. HPV testing detected more ≥CIN3 than cytology (HC2: 35, cobas, CLART: 37, APTIMA: 34, cytology: 31), although statistically the differences were not significant. Cobas and CLART detected significantly more ≥CIN2 than cytology (cobas, CLART: 49, cytology: 39). The proportion of women with false-positive test results (positive test results without ≥CIN3) varied between 3.3% with cytology and 14.9% with cobas. All HPV assays led to significantly more false-positive tests, whereas compared to HC2 cobas and CLART were associated with a significantly higher and APTIMA with a significantly lower proportion. Detection of CIN1 was particularly increased for the three DNA assays. With APTIMA combined with cytological triage, about 20% more women were referred for colposcopy than with cytology screening. With the three DNA assays, the increase was ≥50%. The number of women with repeated testing was twice as high with APTIMA and almost five times as high with cobas compared to cytology. To our knowledge, Horizon was the only study set in routine practice that compared more than two HPV assays in the same women while also ascertaining the histological status of women with normal cytology/HPV-positive test results. HPV-based screening of Danish women aged 30-65 detected more high-grade CIN but decreased the screening specificity, and increased the demand for additional testing.

AB - In women aged ≥30 years, Human Papillomavirus testing will replace cytology for primary cervical screening. We compared Hybrid Capture 2 (HC2), cobas, CLART, and APTIMA HPV assays with cytology on 2869 SurePath samples from women undergoing routine screening at 30-65 years in Copenhagen, Denmark. Women with cytological abnormalities were managed according to routine recommendations, with 92% completeness. Those with cytology-normal/HPV-positive samples (on any of the four assays) were invited for repeated cytology and HPV testing in 1.5 year, and 58% had additional testing. HPV testing detected more ≥CIN3 than cytology (HC2: 35, cobas, CLART: 37, APTIMA: 34, cytology: 31), although statistically the differences were not significant. Cobas and CLART detected significantly more ≥CIN2 than cytology (cobas, CLART: 49, cytology: 39). The proportion of women with false-positive test results (positive test results without ≥CIN3) varied between 3.3% with cytology and 14.9% with cobas. All HPV assays led to significantly more false-positive tests, whereas compared to HC2 cobas and CLART were associated with a significantly higher and APTIMA with a significantly lower proportion. Detection of CIN1 was particularly increased for the three DNA assays. With APTIMA combined with cytological triage, about 20% more women were referred for colposcopy than with cytology screening. With the three DNA assays, the increase was ≥50%. The number of women with repeated testing was twice as high with APTIMA and almost five times as high with cobas compared to cytology. To our knowledge, Horizon was the only study set in routine practice that compared more than two HPV assays in the same women while also ascertaining the histological status of women with normal cytology/HPV-positive test results. HPV-based screening of Danish women aged 30-65 detected more high-grade CIN but decreased the screening specificity, and increased the demand for additional testing.

U2 - 10.1371/journal.pone.0147326

DO - 10.1371/journal.pone.0147326

M3 - Journal article

C2 - 26789267

VL - 11

SP - 1

EP - 14

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 1

M1 - e0147326

ER -

ID: 155926134